Company Profile

XenoTech LLC
Profile last edited on: 4/19/2019      CAGE: 1NH38      UEI: MAQKL1MN66A9

Business Identifier: Pharmaceutical safety testing and drug metabolism services.
Year Founded
1994
First Award
2006
Latest Award
2006
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1101 West Cambridge Circle Drive
Kansas City, KS 66103
   (913) 438-7450
   info@xenotechllc.com
   www.xenotechllc.com
Location: Single
Congr. District: 03
County: Wyandotte

Public Profile

As of August 2008, XenoTech, LLC has operated as a subsidiary of Japanese-based Sekisui Chemical Co. Ltd., Sekisui America Corporation. XenoTech is organized around drug metabolism and pharmacokinetics products to include hepatocytes that are used in drug discovery and preclinical drug development to perform experiments requiring intact cellular systems; subcellular fractions that are used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of drug candidates; and Kupffer Cells, which are macrophages endogenous to the liver and modulate hepatic inflammation and injury associated with various pathophysiologies and toxicities. The company also features media and reagents products designed for use in in-vitro ADME studies; recombinant enzymes products used to support drug discovery and preclinical drug development services; P450 substrates and metabolites that are used in early-stage drug discovery services; and custom products. In addition, it distributes Cypex's Bactosomes, cytochrome P450 substrates and metabolites, in North America; and offers analytical, biologic, and consulting services, as well as drug metabolism and transporters, and enzyme induction and inhibition, in vivo ADME, lysosomal trapping, and pharmacology services. The company markets its products through a network of distributors in Japan, Europe, India, Singapore, China, South Korea, Africa, and Taiwan. XenoTech, LLC has a strategic alliance with XenoGesis.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $95,765
Project Title: Enzyme induction in freshly isolated human hepatocytes

Key People / Management

  Toshinari Ohara -- Chief Executive Officer

  Andrew Parkinson -- President

  Joanna Barbara -- Vice President, Scientific Operations

  Maciej Czerwinski -- Division Director of Consulting

  Angela Kreps -- Vice President of Commercial Operations

  Phil Marquardt

  Brian Ogilvie -- Vice President, Scientific Consulting

  Allen Roberson -- Vice President, Finance & Administration

  Darren Warren -- Chief Operating Officer

Company News

There are no news available.